v3.25.1
Business combinations during the period. - Price allocations (Details)
$ in Millions
 12 Months Ended
Jun. 21, 2022
EUR (€)
Dec. 31, 2024
EUR (€)
Dec. 31, 2023
EUR (€)
Dec. 31, 2022
EUR (€)
Jun. 21, 2022
USD ($)
Business combinations during the period          
Exchange differences on goodwill   € 453,000 € (256,000)    
Goodwill on 12/31/2022   70,010,000 69,557,000 € 69,813,000  
Net cash outflow arising on acquisition (2022)          
Cash out from acquisition of subsidiaries, net of cash acquired € 115,270,000   7,000,000 115,270,000  
Cash used in operating activities for other liabilities related to the acquisition of subsidiaries (2022) 28,164,000 3,598,000   28,164,000  
Cell Point Acquisition          
Business combinations during the period          
Intangible assets other than goodwill 120,517,000        
Property, plant and equipment 1,289,000        
Other non-current assets 81,000        
Trade and other receivables 162,000        
Cash and cash equivalents 3,179,000        
Other current assets 1,254,000        
Deferred tax liabilities (22,368,000)        
Trade and other liabilities (32,789,000)        
Net assets acquired 71,325,000        
Consideration paid in cash 107,750,000        
Deferred consideration 5,808,000        
Fair value of contingent consideration 20,211,000        
Fair value of total consideration 133,769,000        
Goodwill on 6/21/2022. 62,444,000        
Goodwill on 12/31/2022   62,400,000   62,444,000  
Net cash outflow arising on acquisition (2022)          
Consideration paid in cash 107,750,000        
Less: Cash and cash equivalents balances acquired. (3,179,000)        
Cash out from acquisition of subsidiaries, net of cash acquired 104,571,000   € 7,000,000    
Cash used in operating activities for other liabilities related to the acquisition of subsidiaries (2022) 28,164,000        
Cell Point Acquisition | Book value          
Business combinations during the period          
Property, plant and equipment 1,289,000        
Other non-current assets 81,000        
Trade and other receivables 162,000        
Cash and cash equivalents 3,179,000        
Other current assets 1,254,000        
Trade and other liabilities (32,789,000)        
Net assets acquired (26,824,000)        
Net cash outflow arising on acquisition (2022)          
Less: Cash and cash equivalents balances acquired. (3,179,000)        
Cell Point Acquisition | Adjustment          
Business combinations during the period          
Intangible assets other than goodwill 120,517,000        
Deferred tax liabilities (22,368,000)        
Net assets acquired 98,149,000        
AboundBio          
Business combinations during the period          
Intangible assets other than goodwill 4,053,000        
Property, plant and equipment 965,000        
Other non-current assets 4,000        
Cash and cash equivalents 4,279,000        
Other current assets 536,000        
Deferred tax liabilities (907,000)        
Trade and other liabilities (587,000)        
Current deferred income (474,000)        
Net assets acquired 7,869,000        
Consideration paid in cash 14,976,000        
Fair value re-measurement of previously held equity investment 342,000        
Fair value of total consideration 15,318,000       $ 14
Goodwill on 6/21/2022. 7,449,000        
Exchange differences on goodwill (80,000)        
Goodwill on 12/31/2022   € 7,600,000   € 7,369,000  
Net cash outflow arising on acquisition (2022)          
Consideration paid in cash 14,976,000        
Less: Cash and cash equivalents balances acquired. (4,279,000)        
Cash out from acquisition of subsidiaries, net of cash acquired 10,698,000        
AboundBio | Book value          
Business combinations during the period          
Property, plant and equipment 965,000        
Other non-current assets 4,000        
Cash and cash equivalents 4,279,000        
Other current assets 536,000        
Trade and other liabilities (587,000)        
Current deferred income (474,000)        
Net assets acquired 4,723,000        
Net cash outflow arising on acquisition (2022)          
Less: Cash and cash equivalents balances acquired. (4,279,000)        
AboundBio | Adjustment          
Business combinations during the period          
Intangible assets other than goodwill 4,053,000        
Deferred tax liabilities (907,000)        
Net assets acquired € 3,146,000